Cambridge Healthtech Institute’s Inaugural
Radiopharmaceutical Therapies
Precision Medicine for Cancer
May 13-14, 2025
Radiopharmaceutical therapies are a rapidly advancing approach in medicine that leverages the unique properties of radioactive isotopes to selectively target and treat various diseases, particularly cancers. These targeted therapies have shown promising results in the treatment of a variety of solid tumors and hematological malignancies, including prostate cancer, neuroendocrine tumors, lymphoma, and select forms of leukemia. As the field continues to advance, researchers are exploring new targeting strategies, novel radioisotope applications, and personalized treatment approaches to further improve patient outcomes. We are inviting leading experts to share their case studies and showcase the tremendous potential of radiopharmaceutical therapies to transform patient care.
Coverage will include, but is not limited to:
- State-of-the-Industry Panel Discussion
- Engineering Strategies to Enhance Therapeutic Efficacy
- Targeting platforms and strategies
- Alpha vs. beta emitters
- Pairing radionuclide with targeting platform and patient/tumor types
- Approaches to Theranostic Pairing of Therapeutics with Diagnostics/Biomarkers
- Clinical Trials, Dosimetry, Treatment Sequencing, and Patient Management
- Emerging Targets and New Indications
The deadline for priority consideration is October 11, 2024.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: